How do recent RxPonder results affect your adjuvant therapy choice for premenopausal women with HR+/HER2 negative breast cancer with 1-3 positive LNs?

Would you consider an Oncotype or Mammaprint? Would your management change if the patient had 1-3 positive LNs on SLNBx (as opposed to ALND)?

Answer from: Medical Oncologist at Academic Institution

In the RxPONDER clinical trial, all premenopausal patients with HR+ HER2-negative breast cancer with 1-3 positive LNs had a benefit from adjuvant chemotherapy regardless of their Oncotype DX RS. Therefore, there would not be a need to send for an Oncotype or Mammaprint. This management would not cha...

Comments

Medical Oncologist at Gerard J Ventura MD, FACP
At least for premenopausal patients, the data seem...

Medical Oncologist at Memorial Sloan Kettering Cancer Center
What is the interpretation of LN micro metastasis ...

Please select the option that best describes you:

How do recent RxPonder results affect your adjuvant therapy choice for premenopausal women with HR+/HER2 negative breast cancer with 1-3 positive LNs?

Related Questions